2016

10732 bookmarks
Custom sorting
OptoCeutics | EVY
OptoCeutics | EVY
Find light in the darkness of Alzheimer's and Dementia. Feel better in 5 weeks or get fully reimbursed. See how EVY LIGHT® could help you!
·optoceutics.com·
OptoCeutics | EVY
Yes, I’m Excited about Allulose - David Perlmutter M.D.
Yes, I’m Excited about Allulose - David Perlmutter M.D.
Allulose, a rare sugar, has gained significant attention in recent years due to its numerous health benefits, primarily concerning metabolic health. To be sure, it seems like it is everywhere …
·drperlmutter.com·
Yes, I’m Excited about Allulose - David Perlmutter M.D.
Sodom and Gomorrah - YouTube
Sodom and Gomorrah - YouTube
Ron Wyatt's discovery of Sodom and Gomorrah is miraculous- the evidence was hidden until just the right time! the remains are spectacular to view and the mes...
·youtube.com·
Sodom and Gomorrah - YouTube
Kimera Labs
Kimera Labs
Leading exosome biotechnology laboratory. Specializes in the production of perinatal MSC-derived exosome products for cosmetic treatment. Request a lab tour.
·kimeralabs.com·
Kimera Labs
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression | ACS Biomaterials Science & Engineering
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression | ACS Biomaterials Science & Engineering
Glioblastoma presents significant challenges in neuro-oncology due to its aggressive nature, drug resistance, and restrictions imposed by the blood–brain barrier. Ivermectin (IVM), known for its antiparasitic properties, has been highlighted as a promising treatment for tumors and an alternative therapy for glioma, although it exhibits low oral bioavailability. Therefore, we investigated the in vivo effect of IVM encapsulation in organic and inorganic nanosystems, first screened in vitro against different tumor cells and subsequently evaluated in vitro and in vivo glioma models. We produced IVM-loaded poly(ε-caprolactone) nanocapsules (IVM-NC) using the interfacial deposition method, and IVM-loaded nanostructured silica particles (IVM-MCM) by loading IVM into commercial MCM-41 silica using the incipient wetness method. IVM-NC had a nanometric size (190 nm), a unimodal size distribution (span <2), and a high encapsulation efficiency (100% at 1 mg/mL). IVM-MCM exhibited a well-organized hexagonal mesoporous structure and high drug loading (0.12 mg/mg). Nanoencapsulated IVM significantly reduced the viability of various cancer cell lines, particularly glioma cell lines, which led us to evaluate them in a preclinical glioma model. We implanted adult male Wistar rats with C6 cells. Intranasal delivery of IVM-NC (60 μg/rat/day for 10 days) resulted in a larger decrease in tumor size compared with the group treated with free IVM, along with histopathological improvements. Treatment with IVM-MCM did not decrease the tumor size. However, both treatments were well-tolerated, with no adverse effects on weight, biochemical, or hematological parameters, or lung histology. Furthermore, the effective equivalent dose of IVM (26 μg/kg) in the rat glioma model was lower than the approved human dose for parasitic infections. This study marks the first exploration of IVM delivery to the brain. In summary, nasal administration of nanoencapsulated IVM via nanocapsules presents a promising avenue for targeted therapy against glioblastoma, with potential implications for clinical translation.
·pubs.acs.org·
Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression | ACS Biomaterials Science & Engineering